首页> 外文期刊>Molecular and Cellular Biochemistry: An International Journal for Chemical Biology >Mitigation of postischemic cardiac contractile dysfunction by CaMKII inhibition: Effects on programmed necrotic and apoptotic cell death
【24h】

Mitigation of postischemic cardiac contractile dysfunction by CaMKII inhibition: Effects on programmed necrotic and apoptotic cell death

机译:CaMKII抑制减轻局部缺血性心脏收缩功能障碍:对程序性坏死和凋亡细胞死亡的影响

获取原文
获取原文并翻译 | 示例
           

摘要

While Ca2+/calmodulin-dependent protein kinase II (CaMKII) has been suggested to be an important protein regulating heart function upon ischemia/reperfusion (I/R), the mechanisms responsible are not fully known. Furthermore, it is not known whether CaMKII activation can modulate necroptosis, a recently described form of programmed cell death. In order to investigate these issues, Langendroff-perfused rat hearts were subjected to global ischemia and reperfusion, and CaMKII inhibition was achieved by adding the CaMKII inhibitor KN-93 (0.5 μmol/dm3) to the perfusion solution before the induction of ischemia. Immunoblotting was used to detect changes in expression of proteins modulating both necroptotic and apoptotic cell death. CaMKII inhibition normalized I/R induced increases in expression of necroptotic RIP1 and caspase-8 along with proteins of the intrinsic apoptotic pathway, namely cytochrome c and caspase-9. In addition, it increased the Bcl-2/Bax ratio and reduced caspase-3 and cleaved PARP1 content suggesting reduction of cell death. These changes coexisted with improvement of postischemic contractile function. On the other hand, there was no correlation between levels of pT287-CaMKIIδ and LVDP recovery after I/R. These results demonstrate for the first time that CaMKII inhibition may mitigate cardiac contractile dysfunction, at least partially, by limiting the contents of not only apoptotic, but also necroptotic proteins. Phosphorylation of CaMKII seems unlikely to determine the degree of postischemic recovery of contractile function.
机译:虽然已经提出了Ca2 + /钙调蛋白依赖性蛋白激酶II(CaMKII)是调节缺血/再灌注(I / R)时心脏功能的重要蛋白,但其作用机理尚不完全清楚。此外,尚不知道CaMKII激活是否可以调节坏死病,最近描述的程序性细胞死亡形式。为了研究这些问题,对朗格德罗夫灌注的大鼠心脏进行了局部缺血和再灌注,并且在诱导缺血之前,通过在灌注溶液中添加CaMKII抑制剂KN-93(0.5μmol/ dm3)来实现对CaMKII的抑制。免疫印迹用于检测调节坏死性和凋亡性细胞死亡的蛋白质表达的变化。 CaMKII抑制归一化的I / R诱导的坏死性RIP1和caspase-8以及固有凋亡途径的蛋白,即细胞色素c和caspase-9的表达增加。此外,它增加了Bcl-2 / Bax的比例,降低了caspase-3的含量,并裂解了PARP1的含量,提示细胞死亡减少。这些变化与缺血后收缩功能的改善并存。另一方面,I / R后pT287-CaMKIIδ的水平与LVDP恢复之间没有相关性。这些结果首次证明,通过不仅限制凋亡的蛋白质,而且限制坏死性蛋白质的含量,CaMKII抑制作用可以至少部分缓解心脏收缩功能障碍。 CaMKII的磷酸化似乎不太可能决定缺血后收缩功能的恢复程度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号